AdvaMed® Advancements: Q4 2025 Report
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
Emerging Policy Response Resources
2025 Emerging Policy Response Resources
AdvaMed® Advancements: Q3 2025 Report
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to…
The Economic Impact of the Medical Technology Industry 2024
Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy
Tariff-related Litigation Update – 9/12
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Tariff-related Litigation Update – 9/5
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Tariff-related Litigation Update – 8/22
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Tariff-related Litigation Update – 8/15
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Scott Whitaker Op-Ed: Medtech is vital to a healthier America
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
Tariff-related Litigation Update – 7/25
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 25, 2025.
Tariff-related Litigation Update – 7/18
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 18, 2025.